Skip to main content
Scott Lippman, MD, Oncology, La Jolla, CA

ScottM.LippmanMD

Oncology • La Jolla, CA

Head & Neck Cancer, Hematologic Oncology, Thoracic Cancer

Professor of Medicine, UC San Diego Moores Cancer Center

Join to view full profile

Dr. Lippman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Lippman's full profile

Already have an account?

Education & Training

  • University of Arizona College of Medicine-Tucson
    University of Arizona College of Medicine-TucsonFellowship, Hematology and Medical Oncology, 1985 - 1987
  • Stanford Health Care-Sponsored Stanford University
    Stanford Health Care-Sponsored Stanford UniversityFellowship, Hematology, 1984 - 1985
  • UCLA David Geffen School of Medicine/UCLA Medical Center
    UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 1983 - 1984
  • Los Angeles County-Harbor-UCLA Medical Center
    Los Angeles County-Harbor-UCLA Medical CenterInternship, Internal Medicine, 1981 - 1982
  • Johns Hopkins University School of Medicine
    Johns Hopkins University School of MedicineClass of 1981

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1981 - 2025
  • AZ State Medical License
    AZ State Medical License 1987 - 2025
  • TX State Medical License
    TX State Medical License 1988 - 2013
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Association of American Physicians
  • Fellow (FASCO) American Society of Clinical Oncologists, 2009
  • Super Doctor SuperDoctors.com
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Analysis of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophageal Junction and Gastric Adenocarcinoma  
    Lawrence Leichman, Jason K Sicklick, Shumei Kato, Kaitlyn Kelly, Scott M Lippman, Clinical Cancer Research

Lectures

  • Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial 
    University of California, San Diego, La Jolla, California - 4/6/2013
  • Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial 
    University of California, San Diego, San Diego, California - 10/2/2013
  • Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial 
    University of California, San Diego, San Diego, California - 10/2/2013

Authored Content

  • Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity TrialJune 2018
  • Determinants and Prognostic Value of Quality of Life in Patients with Pancreatic Ductal AdenocarcinomaFebruary 2018
  • Determinants and Prognostic Value of Quality of Life in Patients with Pancreatic Ductal AdenocarcinomaFebruary 2018

Press Mentions

  • Parsing the Genetic Drivers of Head and Neck Cancers
    Parsing the Genetic Drivers of Head and Neck CancersNovember 21st, 2022
  • Lung Cancer Screening Dramatically Increases Long-Term Survival Rate
    Lung Cancer Screening Dramatically Increases Long-Term Survival RateNovember 21st, 2022
  • Parsing the Genetic Drivers of Head and Neck Cancers
    Parsing the Genetic Drivers of Head and Neck CancersNovember 17th, 2022
  • Join now to see all

Grant Support

  • M D Anderson Cancer Center Head &Neck SporeNational Cancer Institute2008–2011
  • CA: Administrative CoreNational Cancer Institute2008–2011
  • Insulin-Like Growth Factor Axis And Insulin Resistance In PcptNational Cancer Institute2007–2009
  • Core---Pathology/GenotypingNational Cancer Institute2007–2009
  • Oxidative Damage And DNA Repair In The PcptNational Cancer Institute2005–2009
  • Genotypic And Phenotypic Studies Of Inflammation In PcptNational Cancer Institute2005–2009
  • Diet And Diet-Related Factors In The PcptNational Cancer Institute2005–2009
  • Core--Biostatistics/Data ManagementeNational Cancer Institute2005–2009
  • Androgen Metabolism In The PcptNational Cancer Institute2005–2009
  • Molecular-Based Therapy For Oral Cancer PreventionNational Cancer Institute2004–2009
  • Biology Of The Prostate Cancer Prevention Trial (PCPT)National Cancer Institute2005–2008
  • U10 Ful Member Application Affiliated With SWOGNational Cancer Institute2004–2008
  • Oral Cancer Prevention With Molecular Targeting TherapyNational Cancer Institute2004–2008
  • Phase I &Ii Clinical Trials Of Chemopreventive AgentsNational Cancer Institute2007
  • MD Anderson Cancer Center Spore In Head And Neck CancerNational Cancer Institute2007
  • Igf-1axis And Insulin Resistance In PcptNational Cancer Institute2005–2006
  • Core--Pathology/GenotypingNational Cancer Institute2005–2006
  • Core A "Administration Core"National Cancer Institute2005
  • AdministrationNational Cancer Institute2004
  • Translational Study Of Retinoid Reversal Or Oral CarcinogenesisNational Cancer Institute1997–2002
  • Biologic Approach To Therapy Of Aggressive Skin CancerNational Cancer Institute1996–2002
  • Phase III Study Of Fenretinide In Bladder CarcinofenesisNational Cancer Institute1997–2001
  • Phase II Clinical Trials Of New Chemoprventive AgentsDivision Of Cancer Prevention And Control1998–1999
  • Chemoprevention Trial In Oral PremalignancyNational Cancer Institute1996

Professional Memberships

Dr. Scott Lippman, Dr. Scott Lippman, MD, Dr. S Lippman, Dr. Scott M. Lippman